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Background: Many patients at high cardiovascular risk do not reach targets for low-density 
lipoprotein cholesterol (LDL-C) and blood pressure (BP). Depression is a frequent comorbidity 
in these patients and contributes to poor medication adherence.
Objective: The aim of this study was to elucidate the associations between adherence to lipid- 
and BP-lowering drugs, the diagnosis of depression, and the control of LDL-C and BP.
Patients and methods: This study was conducted as multicenter, single-visit cross-sectional 
study in Germany. Adherence was assessed by the Morisky Medication Adherence Scale-8 
(MMAS-8), and depression was assessed as documented in the patient chart.
Results: A total of 3,188 ambulatory patients with hypercholesterolemia (39.8%), stable coronary 
artery disease (CAD; 7.4%), or both (52.9%) were included. Patients had a history of myocardial 
infarction (30.8%), diabetes (42.0%), were smokers (19.7%), and 16.1% had the investigator-
reported diagnosis of depression. High or moderate adherence to lipid-lowering medication 
compared to low adherence was associated with lower LDL-C levels (105.5±38.3 vs 120.8±42.4 
mg/dL) and lower BP (systolic BP 133.4±14.5 vs 137.9±13.9 mmHg, diastolic BP 78.3±9.6 vs 
81.8±9.6 mmHg) and with a higher proportion of patients achieving the guideline-recommended 
LDL-C (16.9% vs 10.1%) and BP target (52.2% vs 40.8%, all comparisons P,0.0001). Adher-
ence was worse in patients with depression. Correspondingly, patients with depression showed 
higher LDL-C levels, higher BP, and a lower probability of achieving the LDL-C and BP goal. 
Medication adherence correlated between BP- and lipid-lowering medications.
Conclusion: Self-reported medication adherence can be easily obtained in daily practice. A low 
adherence and the diagnosis of depression identify patients at risk for uncontrolled LDL-C and 
BP who likely benefit from intensified care.
Keywords: adherence, blood pressure, cardiovascular disease, coronary artery disease, depres-
sion, LDL cholesterol, lipids, MMAS-8, prevention, statin
Introduction
Cardiovascular diseases (CVD) such as coronary artery disease (CAD) are the leading 
cause of death worldwide.1 Large randomized controlled trials have shown that 
lowering of low-density lipoprotein cholesterol (LDL-C) and blood pressure (BP) is 
beneficial in primary and secondary prevention of CVD.2,3
The current European Society of Cardiology (ESC)/European Atherosclerosis Society 
(EAS) guidelines recommend achieving LDL-C levels of ,70 and ,100 mg/dL for 
patients at very high and high risk, respectively.4 However, despite the  availability of 
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effective and well-tolerated drugs, the LDL-C of the majority 
of patients remains uncontrolled.5–7 There are several factors 
influencing the risk factor control including adherence to medi-
cation defined as “the extent to which patients take medications 
as prescribed by their health care providers”.8 Adherence to 
lipid- and BP-lowering medication gets worse over time. A few 
months after initiation, a very significant part of the patients 
stops taking the prescribed medication.9–11 Poor statin adherence 
has been linked to cardiovascular and all-cause mortality.12–14 
Adherence to statins is associated with improved LDL-C lev-
els.15 Similarly, improving adherence to BP medication has 
been shown to improve BP control and clinical outcomes.16,17 
However, it is not well studied whether the data regarding 
adherence to BP-lowering medication can be extrapolated 
to adherence to lipid-lowering medication. In general, poor 
adherence to cardiovascular medication causes a considerable 
proportion of cardiovascular events and deaths.18,19
Up to 20% of patients with CVD suffer from major 
depression.20 A bidirectional relationship has been assumed 
between these two disease entities.21 Depression is likely to 
contribute to non-adherence to lipid- and BP-lowering drugs, 
which may represent a link between depressive symptoms 
and risk of CVD.22
Therefore, the aim of this study was to elucidate the 
association between adherence to lipid- and BP-lowering 
drugs and the diagnosis of depression.
Patients and methods
This multicenter, single-visit cross-sectional study was 
conducted in Germany between March 15, 2017, and 
September 15, 2017. General practitioners and specialists 
treating outpatients were encouraged to include 10 consecu-
tive patients scheduled for routine appointment. Inclusion 
criteria were as follows:
•	 $18 years of age
•	 Hypertension as documented diagnosis
•	 Hypercholesterolemia or stable CAD as documented 
diagnosis
•	 Current medication with at least one antihypertensive 
drug
•	 Current medication with a statin
•	 Signed informed consent.
Patients who had been hospitalized because of a cardio-
vascular event within the past 3 months were excluded.
After the patients had signed the informed consent, the 
participating physicians collected the following data:
•	 Age and sex
•	 Cardiovascular risk factors and comorbidities
•	 Depression (yes/no)
•	 Current antihypertensive medication
•	 Current statin medication
•	 Systolic and diastolic BP (SBP, DBP) values, measured 
at the documentation visit according to the ESC/European 
Society of Hypertension (ESH) guideline23
•	 Control of hypertension according to physician
•	 Serum lipid levels (total cholesterol, LDL-C, high-density 
lipoprotein cholesterol [HDL-C], triglycerides), if mea-
sured within the past 12 months
•	 Control of LDL-C according to physician
•	 Eligibility of the patient for taking a fixed-dose combina-
tion (FDC) according to the physician and the reason for 
prescribing FDC pills.
Adherence to antihypertensive and lipid-lowering 
medication was determined using the Morisky Medication 
Adherence Scale-8 (MMAS-8), a self-report questionnaire 
comprising eight items.24 MMAS-8 values of ,6 were clas-
sified as “low adherence”, 6 or 7 as “moderate adherence”, 
and 8 as “high adherence”. Results regarding adherence are 
based on the MMAS-8 scores for adherence to lipid-lowering 
medication. LDL-C goals were defined according to the 
current ESC/EAS guideline as ,70 mg/dL in patients with 
CAD or at very high cardiovascular risk and ,100 mg/dL 
in patients at high cardiovascular risk.4
The study protocol was in accordance with the ethical 
guidelines of the 1975 Declaration of Helsinki and approved by 
the ethics committee (Ärztekammer des Saarlandes 307/16).
statistical analyses
Categorical values are expressed as the percentage of the 
evaluable patients for each variable, excluding patients with 
missing data. Continuous data are expressed as mean ± SD. 
Categorical data were compared using the chi-squared test; 
for continuous data, the two-sample t-test was used. For 
comparison of BP and LDL-C control according to ESC 
guideline vs investigator, the McNemar test was utilized. 
Logistic regression was used to identify factors associated 
with adherence, LDL-C control, and BP control. The fol-
lowing factors were included in the regression analyses: age 
(defined as males older than 55 years and females older than 
65 years), sex, smoking, depression, history of myocardial 
infarction, diabetes, peripheral vascular disease, stroke or 
transient ischemic attack, chronic heart failure, renal disease, 
positive family history of CAD, positive family history of 
hypercholesterolemia, adherence to, respectively, lipid- and 
BP-lowering medication, single-pill combination treatment 
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Medication adherence, depression, and control of lDl-c/blood pressure
hypercholesterolemia. The analyses were performed with 
SAS, version 9.4 (SAS Institute Inc., Cary, NC, USA). A 
P-value of ,0.05 was considered statistically significant.
Results
A total of 1,247 physicians participated, who included 
3,312 patients (76.5% included by general practitioners, 
23.5% by specialists), of whom 3,188 were available for 
final analysis.
Demographic characteristics and 
risk factors
The baseline characteristics are summarized in Table 1. 
Of the 3,188 patients, 60.9% were male, 61.4% were aged 
between 60 and 79 years. 39.8% of the patients had a diagno-
sis of hypercholesterolemia, 7.4% had a diagnosis of stable 
CAD, and 52.9% had both diagnoses. 30.8% of the patients 
had a history of myocardial infarction. The most present 
cardiovascular risk factors were age (76.3%, defined as males 
older than 55 years or females older than 65 years), diabetes 
(42.0%), and positive family history of CAD (28.8%); 19.7% 
of the patients were smoking.
Patients with depression
Depression was diagnosed in 16.1% of the patients (n=512). 
The majority of patients with depression were female 
(57.4%), corresponding to 23.9% of the female patients and 
11.4% of the male patients were with depression (P,0.0001). 
Among the patients with depression, a higher proportion had a 
history of previous stroke or transient ischemic attack (16.8% 
vs 10.6%), a positive family history of hypercholesterolemia 
(32.2% vs 23.6%), chronic heart failure (26.4% vs 17.6%), 
renal disease (20.5% vs 13.8%), and familial hypercholes-
terolemia (34.0% vs 24.0%, for all comparisons P,0.0001). 
Patients with depression were more often smokers (24.4% 
vs 18.8%, P=0.0032) and were prescribed more pills per day 
(7.2±3.3 vs 6.2±3.2, P,0.0001). Adherence to lipid-lowering 
medication was worse in patients with depression (Table 1). 
In logistic regression analyses, depression was associated 
with poor BP control (P=0.0211), poor LDL-C control 
(P=0.0452), and poor medication adherence (P,0.0001).
Patients with low vs moderate or high adherence 
to lipid-lowering medication
42.0% of the patients exhibited low, 28.1% moderate, and 
29.9% high self-reported adherence to their lipid-lowering 
medication. There were no significant differences between 
patients with high vs moderate adherence in LDL-C levels 
as well as LDL-C and BP control. Therefore, patients with 
high and moderate adherence were analyzed as one group and 
compared to patients with low adherence (Figure 1).
In comparison to patients with moderate or high adher-
ence, patients with low adherence were younger; a higher 
proportion had a family history of CAD (33.2% vs 25.0%) 
and hypercholesterolemia (29.5% vs 21.7%) and a history of 
depression (20.0% vs 13.4%, for all comparisons P,0.0001), 
peripheral vascular disease (13.3% vs 10.1%, P=0.0074), and 
familial hypercholesterolemia (28.9% vs 22.6%, P,0.0001). 
Patients with low adherence were significantly more often 
smokers (27.1% vs 14.7%, P,0.0001). The number of daily 
doses was comparable in both groups (6.3±3.0 vs 6.5±3.3, 
P=0.2101). There was no correlation between the number of 
daily doses and adherence measured by MMAS-8 (Spear-
man’s correlation coefficient -0.00434, P=0.8118). The data 
are summarized in Table 1.
High adherence was more common in women than in men 
(31.0% vs 25.8%, P=0.0035). However, the proportion of 
low adherence was comparable in men and women (41.7% 
vs 41.1%, P=0.7849).
An FDC treatment was thought to contribute to treatment 
goal attainment in 63.1% of all patients by improving adher-
ence (45.1%), patient convenience (43.8%), cardiovascular 
protection (32.2%), LDL-C control (30.1%), BP control 
(26.2%), and costs (17.2%).
Logistic regression revealed that depression and smoking 
are strongly associated with poor adherence (P,0.0001), 
independent of using the categorized MMAS-8 or the score 
as continuous variable. In the model of MMAS-8 score as 
continuous variable, additional but less strong associations 
with poor adherence were found for stroke (P=0.0456), age 
(men older than 55 years or women older than 65 years, 
P=0.0330), and positive family history of CAD (P=0.0213) 
and hypercholesterolemia (P=0.0041).
Blood pressure
The mean office SBP was 135.3±14.4 mmHg, and the mean 
DBP was 79.8±9.7 mmHg. BP control was achieved in 47.2% 
and 90.9% of the patients according to ESC/ESH guideline 
on hypertension (target ,140/90 mmHg) and as assessed by 
the investigator, respectively (P,0.0001).
In patients with depression, BP was significantly 
higher and BP control was achieved in a significantly 
lower proportion of patients (SBP 138.1±15.6 vs 
134.8±14.1 mmHg, DBP 81.8±10.4 vs 79.4±9.6 mmHg, 
BP control according to ESC guideline 39.1% vs 48.7%, for 
all comparisons P,0.0001, BP control according to investiga-
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Table 1 Demographic parameters, comorbidities, and medication adherence for the total population, for patients with vs without 


























,60 22.3 20.2 22.7 0.23 26.2 19.6 ,0.0001
60–64 14.3 15.9 14.1 0.2754 16.0 13.0 0.0234
65–74 28.2 30.2 27.8 0.2742 26.9 29.5 0.1198
75–79 18.9 19.8 18.7 0.5439 16.4 20.4 0.0051
$80 16.2 13.9 16.6 0.131 14.5 17.5 0.0315
Sex
Female 39.1 57.4 35.5 ,0.0001 38.8 39.7 0.4889
Male 60.9 42.6 64.5 ,0.0001 61.2 60.3 0.0432
Risk factors and comorbidities
hypercholesterolemia 39.8 36.7 39.6 0.2228 39.3 39.0 0.8564
stable cAD 7.4 6.6 7.4 0.5436 7.6 6.6 0.2814
hypercholesterolemia and 
stable cAD
52.9 54.5 51.6 0.2224 51.7 52.8 0.5491
history of myocardial infarction 30.8 28.3 31.3 0.1771 31.7 30.8 0.6186
stroke/transient ischemic attack 11.6 16.8 10.6 ,0.0001 12.8 10.6 0.0598
Positive family history of cAD 28.8 32.2 28.1 0.0596 33.2 25 ,0.0001
Positive family history of 
hypercholesterolemia
25.0 32.2 23.6 ,0.0001 29.5 21.7 ,0.0001
smoker 19.7 24.4 18.8 0.0032 27.1 14.7 ,0.0001
Diabetes 42.0 44.9 41.4 0.1371 43.0 41.0 0.2787
chronic heart failure 19.0 26.4 17.6 ,0.0001 20.1 17.8 0.1119
Depression 16.1 100 0  20.0 13.4 ,0.0001
Peripheral vascular disease 11.6 13.7 11.2 0.1118 13.3 10.1 0.0074
renal disease 14.9 20.5 13.8 ,0.0001 14.5 15.0 0.7014
Familial hypercholesterolemia 25.6 34.0 24.0 ,0.0001 28.9 22.6 ,0.0001
number of daily tablets  
(mean ± sD)
6.4±3.2 7.2±3.3 6.2±3.2 ,0.0001 6.3±3.0 6.5±3.3 0.2101
BP
sBP in mmhg (mean ± sD) 135.3±14.4 138.1±15.7 134.8±14.1 ,0.0001 137.9±13.9 133.4±14.5 ,0.0001
DBP in mmhg (mean ± sD) 79.8±9.7 81.8±10.1 79.4±9.6 ,0.0001 81.8±9.6 78.3±9.6 ,0.0001
BP control according to esc 
guideline
47.2 39.1 48.7 ,0.0001 40.8 52.2 ,0.0001
MMAS-8 questionnaire, lipid-lowering medication
high adherence (score 8) 29.9 21.8 31.4 ,0.0001
Moderate adherence  
(score 6 or 7)
28.1 26.3 28.5 0.3805
low adherence (score ,6) 42.0 51.8 40.1 ,0.0001
MMAS-8 questionnaire, BP-lowering medication
high adherence (score 8) 30.3 21.9 31.9 ,0.0001
Moderate adherence  
(score 6 or 7)
29.0 27.9 29.2 0.6681
low adherence (score ,6) 40.7 50.2 38.9 ,0.0001
Note: Values are in percentage if not stated otherwise.
Abbreviations: BP, blood pressure; cAD, coronary artery disease; DBP, diastolic BP; esc, european society of cardiology; MMAs-8, Morisky Medication Adherence 
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Medication adherence, depression, and control of lDl-c/blood pressure
compared to those with moderate or high adherence had 
higher BP values and worse BP control according to ESC 
guideline and according to the treating physician’s assess-
ment (SBP 137.9±13.9 vs 133.4±14.5 mmHg, DBP 81.8±9.6 
vs 78.3±9.6 mmHg, BP control according to ESC guideline 
40.8% vs 52.2%, BP control according to investigator 87.9% 
vs 93.4%, for all comparisons P,0.0001). BP was higher in 
women than in men (136.2±14.28 vs 134.9±14.24 mmHg, 
P=0.0255), and BP control was achieved in 47.4% of men 
and 45.7% of women (P=0.4032).
In logistic regression analyses, low adherence 
(MMAS-8 ,6) was strongly associated with poor BP control, 
whereas a history of myocardial infarction was associated 
with better BP control (P,0.0001). An association with 
poor BP control was also found for depression (P=0.0211), 
renal disease (P=0.0065), and FDC antihypertensive treat-
ment (P=0.0062).
The data are given in Table 1 and Figure 1A. The com-
parisons of SBP in the six subgroups with low, moderate, and 
high adherence with and without depression are depicted in 
Figure 1 BP (A) and lDl-c control (B) in different subgroups.
Notes: BP (A) and lDl-c control (B) according to esc guideline for the total population, patients with vs without depression and patients with low vs moderate or high 
adherence to BP- and lipid-lowering medication. MMAs-8, ,6: low adherence; MMAs-8, 6–7: moderate adherence; MMAs-8, 8: high adherence.
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Figure 2A and indicate that SBP is related to both parameters. 
The results for DBP were comparable (not shown).
lipid-lowering medication, serum lipid 
levels, and lDl-c control
Mean total cholesterol was 193.9±52.6 mg/dL, LDL-C 
was 112.3±40.8 mg/dL, HDL-C was 54.1±29.2 mg/dL, 
and triglycerides were 148.6±93.7 mg/dL. LDL-C control 
was achieved in 13.9% and 75.8% according to ESC guide-
line and investigator, respectively (P,0.0001). The mean 
score of the MMAS-8 regarding lipid-lowering medication 
was 5.6±2.3.
Patients with depression were characterized by signifi-
cantly higher LDL-C levels compared to patients without 
depression (116.4±42.0 vs 111.5±40.5 mg/dL, P=0.0238) and 
had a lower probability of achieving LDL-C control accord-
ing to ESC guideline (10.4% vs 14.6%, P=0.0114). LDL-C 
control as reported by the treating physician was not different 
between the groups (78.4% vs 75.3%, P=0.1269). In addi-
tion, triglycerides were significantly higher in patients with 
depression (161.2±93.8 vs 146.1±93.5 mg/dL, P=0.0032). 
The proportion of patients taking statins, ezetimibe, or other 
lipid-lowering medication was comparable. Patients with low 
adherence to lipid-lowering medication showed significantly 
higher LDL-C levels compared to patients with moder-
ate or high adherence (120.8±42.4 vs 105.5±38.3 mg/dL, 
P,0.0001). A smaller proportion of patients with low adher-
ence achieved LDL-C control (LDL-C control according to 
ESC guideline 10.1% vs 16.9% P,0.0001, LDL-C control 
according to investigator 72.4% vs 78.4%, P=0.0001). 
Patients with low adherence had higher levels of triglycerides 
(162.8±94.4 vs 136.6±90.8, P,0.0001). The proportion of 
patients taking statins, ezetimibe, or other lipid-lowering 
medication was comparable. Women had higher LDL-C 
levels than men (120.3±43.6 vs 109.1±38.86 mg/dL, 
P,0.0001), whereas in men triglycerides were higher 
Figure 2 (A) sBP in patients with low, moderate, and high adherence with and without depression. (B) lDl-c levels in patients with low, moderate, and high adherence 
with and without depression.
Notes: (A) low adherence: depression vs no depression: P=0.0007, moderate adherence: depression vs no depression: P=0.0978, high adherence: depression vs no 
depression: P=0.2765; depression: low vs moderate adherence: P=0.0015, moderate vs high adherence: P=0.6904, no depression: low vs moderate adherence: P,0.0001, 
moderate vs high adherence: P=0.8798. (B) low adherence: depression vs no depression: P=0.9571, moderate adherence: depression vs no depression: P=0.2460, high 
adherence: depression vs no depression: P=0.1827; depression: low vs moderate adherence: P=0.0224, moderate vs high adherence: P=0.8997, no depression: low vs 
moderate adherence: P,0.0001, moderate vs high adherence: P=0.6721. MMAs-8, ,6: low adherence; MMAs-8, 6–7: moderate adherence; MMAs-8, 8: high adherence.
Abbreviations: lDl-c, low-density lipoprotein cholesterol; MMAs-8, Morisky Medication Adherence scale-8; sBP, systolic blood pressure.
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Medication adherence, depression, and control of lDl-c/blood pressure
(152.9±97.15 vs 142±86.7 mg/dL, P=0.0081) and HDL-C 
was lower (51.4±28.57 vs 57.9±24.45 mg/dL, P,0.0001). 
LDL-C control according to guideline was documented in 
15.5% of men and 10.8% of women (P=0.0006).
Logistic regression revealed that male sex (P=0.0006), 
stroke (P=0.0014), and statin/ezetimibe single-pill combina-
tion treatment (P=0.0005) were associated with better LDL-C 
control, whereas depression (P=0.0452), renal disease 
(P=0.0071), and low adherence (MMAS-8 ,6, P=0.0015) 
were associated with worse LDL-C control. The data are 
given in Table 2 and Figure 1B.
The comparisons of LDL-C levels in the six subgroups 
with low, moderate, and high adherence with and without 
depression are depicted in Figure 2B and indicate that serum 
LDL-C levels are related to both parameters.
comparison of adherence to BP- vs 
lipid-lowering medication
The results of the MMAS-8 scores for BP- and lipid-lowering 
medication were compared and showed a significant correla-
tion (Figure 3, Spearman’s correlation coefficient 0.92059, 
P,0.0001).
Discussion
This study reports three important findings. The data dem-
onstrate that low self-reported medication adherence is 
strongly associated with insufficient LDL-C and BP control. 
The information on medication adherence can be reliably 
obtained in daily practice using the MMAS-8 questionnaire. 
Second, the clinical diagnosis of depression is associated 
with low LDL-C and BP target attainment. Low adherence 
and depression identify individuals among the cardiovascular 
high-risk population who might benefit from intensified care. 
Third, adherence to lipid-lowering medication correlates 
with adherence to BP-lowering medication. This information 
extends previous data from the literature10,11,16,17,25 on medi-
cation adherence to the situation in lipid lowering, which is 
closely associated with BP control.
Control of LDL-C as recommended by the current ESC/
EAS guideline4 was achieved in only 13.9% of the patients in 
this study. The poor LDL-C control is in line with previous 
reports of LDL-C goal attainment in USA and in Europe, 
which ranges between 20% and 30%.5,7,26–28 As shown 
recently, potentially 73.9% of all patients at very high risk 
are able to reach the LDL-C goal of ,70 mg/dL if high-dose 
statins and ezetimibe are used at appropriate doses.29 Simi-
larly, the ESC/ESH BP targets are achieved in only 50%–60% 
of the patients in USA and in Europe.7,23,30,31
Several reasons for the underutilization of well-proven 
therapies in daily practice have been discussed. One frequent 
reason for not prescribing or up-titrating statins is worries 
about potential side effects, although observed side effects 
occur infrequently and have been shown not to outweigh 
the beneficial effects.32–34 In addition, our data show a lack 
Table 2 serum lipid levels, lDl-c control, and lipid-lowering medication for the total population, patients with vs without depression, 
























Total cholesterol 193.9±52.6 203.5±52.4 192.0±52.5 ,0.0001 206.4±52.9 184.5±51.0 ,0.0001
lDl-c 112.3±40.8 116.4±42.0 111.5±40.5 0.0238 120.8±42.4 105.5±38.3 ,0.0001
Triglycerides 148.6±93.7 161.2±93.8 146.1±93.5 0.0032 162.8±94.4 136.6±90.8 ,0.0001
hDl-c 51.1±29.2 53.3±20.3 54.3±30.7 0.4495 53.8±31.9 53.7±21.0 0.9248
lDl-c controlled according 
to investigator (%)
75.8 78.4 75.3 0.1269 72.4 78.4 0.0001
lDl-c controlled according 
to esc guideline (%)
13.9 10.4 14.6 0.0114 10.1 16.9 ,0.0001
Lipid-lowering medication
statin (%) 80.8 78.1 81.3 0.3677 81.1 80.9 0.2407
statin/ezetimibe FDc (%) 12.1 13.9 11.7 0.1233 11.0 12.8 0.219
Others (%) 4.5 4.4 4.6 0.9092 4.7 4.1 0.3812
ezetimibe (%) 2.6 3.6 2.4 0.1121 3.1 2.2 0.0961
Note: Values are in milligram per deciliter and presented as mean ± sD if not stated otherwise. 
Abbreviations: ESC, European Society of Cardiology; FDC, fixed-dose combination; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; 
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of awareness regarding the guideline-recommended target 
values, reflected in our study by the treating physician’s 
self-reported assessment of LDL-C control being achieved 
in 75.8% of the patients. Similarly, BP control was thought 
to be achieved in 90.9% of the patients when judged by treat-
ing physician as compared to 47.2% according to the current 
ESC/ESH guideline. The discrepancy in BP control between 
guideline recommendation and physicians’ assessment is 
not of the same magnitude compared to the assessment of 
LDL-C control, indicating a different grade of awareness 
and implementation of the guideline recommendations. 
This is further underpinned by the fact that poor BP control 
was much stronger associated with poor medication adher-
ence as patient-related factor than poor LDL-C control was, 
indicating that physicians’ inertia is one main factor in poor 
LDL-C control. This interesting and novel finding indicates 
an important opportunity for future educational activities.
In light of revised BP targets, the number of patients with 
controlled hypertension may become even worse.35,36 It is 
indeed essential to stress the importance of BP lowering to 
reduce major cardiovascular end points and mortality. Based 
on a meta-analysis including more than 600,000 patients, an 
office BP reduction of 10 mmHg is associated with an RR 
reduction in CAD by 17%, stroke by 27%, heart failure by 
27%, and mortality by 13%, respectively.37
There are different methods for assessing adherence 
such as electronic measures, pharmacy refills, plasma/urine 
drug and/or metabolite concentrations, pill counts, and self-
report.38 Importantly, differences in the estimated adherence 
depend on the method used.39 The MMAS-8 self-reported 
questionnaire has the advantage of being relatively quickly 
to answer, easily applicable, and low cost for use in daily 
practice.40,41
In our study, patients with low adherence to lipid-lowering 
medication were younger than those with moderate or high 
adherence. This is in line with studies in patients with chronic 
heart failure and hypertension.25,42 Furthermore, patients 
with low adherence had more CVD risk factors such as 
smoking, hypercholesterolemia, peripheral vascular disease, 
and positive family history of CAD. Therefore, these young 
patients are at high risk for the development and progression 
of CVD with a high potential for improvements in primary 
and secondary prevention by improved adherence. The 
abovementioned findings support the concept of the “healthy 
adherer effect”, meaning that high medication adherence is a 
surrogate marker for overall healthy behavior.43,44
Our results confirm that low adherence correlates with 
fewer patients reaching LDL-C control.45 In our study, the 
rates of goal attainment did not differ significantly between 
moderate and high adherence, indicating that there is a 
Figure 3 correlation of MMAs-8 results for lipid- and BP-lowering medication.
Note: Spearman’s correlation coefficient 0.92059, P,0.0001.
Abbreviations: BP, blood pressure; MMAs-8, Morisky Medication Adherence scale-8.
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certain extent of adherence which should not be undercut to 
reach a treatment goal. A similar result was reported by Chi 
et al.15 A possible explanation is that LDL-C lowering can 
still occur when doses are missed by patients with moderate 
adherence.
Low adherence to lipid-lowering medication not only did 
result in worse LDL-C control but also was associated with 
insufficient BP control in patients treated with antihyperten-
sive drugs, further increasing cardiovascular risk. Our study 
suggests that adherence to BP-lowering medication may 
predict the intake of lipid-lowering medication. This finding 
has very important practical implications. Although several 
studies have proved that FDCs reduce BP to a greater extent 
compared to the components given separately,46–48 this type of 
information is missing for lipid-lowering medications, eg, sta-
tin–ezetimibe combinations. The observed robust correlation 
of the MMAS-8 questionnaires for lipid- and BP-lowering 
medication implies that the data on the potential benefit of 
FDCs may be extrapolated from BP to lipid lowering.
Another important finding of our study is that patients 
with past or present depression are less likely to achieve 
the guideline-recommended LDL-C goal.22,49 Patients with 
depression had more risk factors for CVD such as smoking or 
past stroke and are therefore at even higher risk for progres-
sive CVD. Noteworthy, the treating physician’s assessment 
of LDL-C control did not differ between patients with vs 
without depression in contrast to the goal attainment accord-
ing to guideline, which was significantly worse in patients 
with depression. One might suggest that the symptoms attrib-
utable to depression may have been dominant in the patients’ 
treatment, potentially distracting from somatic problems. 
Patients with depression may benefit from the treatment of 
depression by an improvement in medication adherence.50
Our study shows a higher prevalence of depression in 
women (23.9% vs 11.4% in men). Although depression was 
strongly associated with adherence, sex was no predictor of 
poor adherence. This is further underpinned by a comparable 
proportion of men and women with achieved BP control, 
which was strongly associated with adherence. LDL-C con-
trol was worse in women. Poor LDL-C control in women 
seems to be driven by depression rather than poor adherence, 
suggesting that especially in women LDL-C is an underap-
preciated risk factor prone to physicians’ inertia.
limitations
Our study has some limitations. The cross-sectional study 
design carries limited possibilities for exploring causal 
relationships and does not provide clinical follow-up. 
The consecutive inclusion of the patients was not supervised; 
therefore, selection bias was possible. Depression was not 
diagnosed using special questionnaires or diagnostic criteria, 
but was assessed according to the treating physician’s diag-
nosis; however, this reflects the situation in daily practice. 
Similarly, the self-reported MMAS-8 is less precise and 
overestimates adherence compared to electronic monitor-
ing, pharmacy claims, or refill data or by measuring drug/
metabolite levels in the blood and/or urine;38 however, the 
advantage of the method is the feasibility and practicality in 
daily practice that we documented in our study.
Conclusion
The majority of patients at high cardiovascular risk did not 
reach the guideline-recommended LDL-C und BP goals. 
Low adherence and the diagnosis of depression identified 
individuals at risk for reduced LDL-C and BP control who are 
likely to benefit from intensified care. Self-reported medica-
tion adherence can be easily obtained in daily practice.
Acknowledgments
The study was funded by Servier Deutschland GmbH, 
Germany. Statistical analyses were supported by Pharmalog, 
Institut für klinische Forschung GmbH, Oskar-Messter-
Straße 29, Ismaning, Germany.
Author contributions
JLK and UL designed the study and wrote the article. All 
authors contributed to data analysis, drafting or revising the 
article, gave final approval of the version to be published, and 
agree to be accountable for all aspects of the work.
Disclosure
Julius L Katzmann reports grants from Servier Deutschland 
GmbH, Germany, non-financial support from Pharmalog, 
Institut für klinische Forschung GmbH, Oskar-Messter-
Straße 29, Ismaning, Germany, during the conduct of the 
study; Michael Böhm reports personal fees from Amgen, 
personal fees from Bayer, personal fees from Servier, per-
sonal fees from Medtronic, personal fees from Boehringer 
Ingelheim, nothing from Vifor, personal fees from Bristol 
Myers Squibb, outside the submitted work; and Ulrich Laufs 
report other from Servier, during the conduct of the study. 
The authors report no other conflicts of interest in this work.
References
1. World Health Organization [homepage on the Internet]. Global Health 
Observatory (GHO) data. Available from: http://www.who.int/gho/ncd/
































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1





 2. Collins R, Reith C, Emberson J, et al. Interpretation of the evidence 
for the efficacy and safety of statin therapy. Lancet. 2016;388(10059): 
2532–2561.
 3. Baigent C, Keech A, Kearney PM, et al; Cholesterol Treatment Trial-
ists’ (CTT) Collaborators. Efficacy and safety of cholesterol-lowering 
treatment: prospective meta-analysis of data from 90,056 participants in 
14 randomised trials of statins. Lancet. 2005;366(9493):1267–1278.
 4. Catapano AL, Graham I, de Backer G, et al; ESC Scientific Document 
Group. 2016 ESC/EAS Guidelines for the Management of Dyslipidae-
mias. Eur Heart J. 2016;37(39):2999–3058.
 5. Chiang CE, Ferrières J, Gotcheva NN, et al. Suboptimal Control of 
Lipid Levels: Results from 29 Countries Participating in the Centralized 
Pan-Regional Surveys on the Undertreatment of Hypercholesterolaemia 
(CEPHEUS). J Atheroscler Thromb. 2016;23(5):567–587.
 6. Gitt AK, Lautsch D, Ferrieres J, et al. Low-density lipoprotein choles-
terol in a global cohort of 57,885 statin-treated patients. Atherosclerosis. 
2016;255:200–209.
 7. Kotseva K, Wood D, De Bacquer D, et al; EUROASPIRE Inves-
tigators. EUROASPIRE IV: A European Society of Cardiology 
survey on the lifestyle, risk factor and therapeutic management of 
coronary patients from 24 European countries. Eur J Prev Cardiol. 
2016;23(6):636–648.
 8. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005; 
353(5):487–497.
 9. Egan BM, Li J, Qanungo S, Wolfman TE. Blood pressure and choles-
terol control in hypertensive hypercholesterolemic patients: national 
health and nutrition examination surveys 1988–2010. Circulation. 2013; 
128(1):29–41.
 10. Ewen S, Meyer MR, Cremers B, et al. Blood pressure reductions 
following catheter-based renal denervation are not related to improve-
ments in adherence to antihypertensive drugs measured by urine/plasma 
toxicological analysis. Clin Res Cardiol. 2015;104(12):1097–1105.
 11. Schulz M, Krueger K, Schuessel K, et al. Medication adherence and 
persistence according to different antihypertensive drug classes: 
A retrospective cohort study of 255,500 patients. Int J Cardiol. 2016; 
220:668–676.
 12. Kurlansky P, Herbert M, Prince S, Mack M. Coronary Artery Bypass 
Graft Versus Percutaneous Coronary Intervention: Meds Matter: 
Impact of Adherence to Medical Therapy on Comparative Outcomes. 
Circulation. 2016;134(17):1238–1246.
 13. Daskalopoulou SS, Delaney JA, Filion KB, Brophy JM, Mayo NE, 
Suissa S. Discontinuation of statin therapy following an acute myocar-
dial infarction: a population-based study. Eur Heart J. 2008;29(17): 
2083–2091.
 14. De Vera MA, Bhole V, Burns LC, Lacaille D. Impact of statin adher-
ence on cardiovascular disease and mortality outcomes: a systematic 
review. Br J Clin Pharmacol. 2014;78(4):684–698.
 15. Chi MD, Vansomphone SS, Liu IL, et al. Adherence to statins and 
LDL-cholesterol goal attainment. Am J Manag Care. 2014;20(4): 
e105–e112.
 16. Corrao G, Parodi A, Nicotra F, et al. Better compliance to antihyper-
tensive medications reduces cardiovascular risk. J Hypertens. 2011; 
29(3):610–618.
 17. Mazzaglia G, Ambrosioni E, Alacqua M, et al. Adherence to antihyper-
tensive medications and cardiovascular morbidity among newly diag-
nosed hypertensive patients. Circulation. 2009;120(16):1598–1605.
 18. Chowdhury R, Khan H, Heydon E, et al. Adherence to cardiovascular 
therapy: a meta-analysis of prevalence and clinical consequences. 
Eur Heart J. 2013;34(38):2940–2948.
 19. Böhm M, Schumacher H, Laufs U, et al. Effects of nonpersistence 
with medication on outcomes in high-risk patients with cardiovascular 
disease. Am Heart J. 2013;166(2):306.e1–314.e1.
 20. Sheps DS, Sheffield D. Depression, anxiety, and the cardiovascular sys-
tem: the cardiologist’s perspective. J Clin Psychiatry. 2001;62(Suppl 8): 
12–6; discussion 17–8.
 21. Khawaja IS, Westermeyer JJ, Gajwani P, Feinstein RE. Depression and 
coronary artery disease: the association, mechanisms, and therapeutic 
implications. Psychiatry (Edgmont). 2009;6(1):38–51.
 22. DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for 
noncompliance with medical treatment: meta-analysis of the effects of 
anxiety and depression on patient adherence. Arch Intern Med. 2000; 
160(14):2101–2107.
 23. Mancia G, Fagard R, Narkiewicz K. 2013 ESH/ESC guidelines for the 
management of arterial hypertension: the Task Force for the Manage-
ment of Arterial Hypertension of the European Society of Hypertension 
(ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 
2013;34(28):2159–2219.
 24. Morisky DE, Ang A, Krousel-Wood M, Ward HJ. Predictive validity 
of a medication adherence measure in an outpatient setting. J Clin 
Hypertens (Greenwich). 2008;10(5):348–354.
 25. Gupta P, Patel P, Štrauch B, et al. Biochemical Screening for Nonadher-
ence Is Associated With Blood Pressure Reduction and Improvement 
in Adherence. Hypertension. 2017;70(5):1042–1048.
 26. Laufs U, Karmann B, Pittrow D. Atorvastatin treatment and LDL 
cholesterol target attainment in patients at very high cardiovascular 
risk. Clin Res Cardiol. 2016;105(9):783–790.
 27. Fox KM, Tai MH, Kostev K, Hatz M, Qian Y, Laufs U. Treatment pat-
terns and low-density lipoprotein cholesterol (LDL-C) goal attainment 
among patients receiving high- or moderate-intensity statins. Clin Res 
Cardiol. 2018;107(5):380–388.
 28. Jones PH, Nair R, Thakker KM. Prevalence of dyslipidemia and lipid 
goal attainment in statin-treated subjects from 3 data sources: a retro-
spective analysis. J Am Heart Assoc. 2012;1(6):e001800.
 29. Gitt AK, Lautsch D, De Ferrari G, Horack M, Brudi P, Ferriéres J. 
Consequent use of available oral lipid Lowering agents would bring 
the majority of high-risk patients with coronary heart disease to recom-
mended targets: an estimate based on the DYSIS II Study. Clin Res 
Cardiol. 2018;107(Suppl 1).
 30. Neuhauser HK, Adler C, Rosario AS, Diederichs C, Ellert U. Hyperten-
sion prevalence, awareness, treatment and control in Germany 1998 and 
2008–11. J Hum Hypertens. 2015;29(4):247–253.
 31. Joffres M, Falaschetti E, Gillespie C, et al. Hypertension prevalence, 
awareness, treatment and control in national surveys from England, the 
USA and Canada, and correlation with stroke and ischaemic heart disease 
mortality: a cross-sectional study. BMJ Open. 2013;3(8):e003423.
 32. Mach F, Ray KK, Wiklund O, et al; European Atherosclerosis Society 
Consensus Panel. Adverse effects of statin therapy: perception vs. 
the evidence – focus on glucose homeostasis, cognitive, renal and 
hepatic function, haemorrhagic stroke and cataract. Eur Heart J. 
2018;39(27):2526–2539.
 33. Spence JD, Dresser GK. Overcoming challenges with statin therapy. 
J Am Heart Assoc. 2016;5(1):e002497.
 34. Zhang H, Plutzky J, Shubina M, Turchin A. Continued Statin Prescrip-
tions After Adverse Reactions and Patient Outcomes: A Cohort Study. 
Ann Intern Med. 2017;167(4):221–227.
 35. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/
ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the 
Prevention, Detection, Evaluation, and Management of High Blood 
Pressure in Adults: A Report of the American College of Cardiology/
American Heart Association Task Force on Clinical Practice Guidelines. 
J Am Coll Cardiol. 2018;71(19):e127–e248.
 36. Williams B, Mancia G, Spiering W, et al; ESC Scientific Document 
Group. 2018 ESC/ESH Guidelines for the management of arterial 
hypertension. Eur Heart J. 2018;39(33):3021–3104.
 37. Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for 
prevention of cardiovascular disease and death: a systematic review 
and meta-analysis. Lancet. 2016;387(10022):957–967.
 38. Jeffery RA, Navarro T, Wilczynski NL, et al. Adherence measurement 
and patient recruitment methods are poor in intervention trials to improve 
patient adherence. J Clin Epidemiol. 2014;67(10):1076–1082.
 39. Morris AB, Li J, Kroenke K, Bruner-England TE, Young JM, Murray MD. 
Factors associated with drug adherence and blood pressure con-
trol in patients with hypertension. Pharmacotherapy. 2006;26(4): 
483–492.
 40. Lehmann A, Aslani P, Ahmed R, et al. Assessing medication adherence: 
































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Patient Preference and Adherence
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/patient-preference-and-adherence-journal
Patient Preference and Adherence is an international, peer-reviewed, 
open access journal that focuses on the growing importance of patient 
 preference and adherence throughout the therapeutic continuum. Patient 
satisfaction, acceptability, quality of life, compliance, persistence and their 
role in  developing new therapeutic modalities and compounds to optimize 
clinical  outcomes for existing disease states are major areas of interest for 
the  journal. This journal has been accepted for indexing on PubMed Central. 
The  manuscript management system is completely online and includes a very 
quick and fair peer-review system, which is all easy to use. Visit http://www.
dovepress.com/testimonials.php to read real quotes from published authors.





Medication adherence, depression, and control of lDl-c/blood pressure
 41. Hawkshead J, Krousel-Wood MA. Techniques for Measuring Medica-
tion Adherence in Hypertensive Patients in Outpatient Settings. Dis 
Manag Health Outcomes. 2007;15(2):109–118.
 42. Krueger K, Botermann L, Schorr SG, Griese-Mammen N, Laufs U, 
Schulz M. Age-related medication adherence in patients with chronic 
heart failure: A systematic literature review. Int J Cardiol. 2015;184: 
728–735.
 43. Böhm M, Lloyd SM, Ford I, et al. Non-adherence to ivabradine and 
placebo and outcomes in chronic heart failure: an analysis from SHIFT. 
Eur J Heart Fail. 2016;18(6):672–683.
 44. Laufs U, Rettig-Ewen V, Böhm M. Strategies to improve drug adher-
ence. Eur Heart J. 2011;32(3):264–268.
 45. Bermingham M, Hayden J, Dawkins I, et al. Prospective analysis of 
LDL-C goal achievement and self-reported medication adherence among 
statin users in primary care. Clin Ther. 2011;33(9):1180–1189.
 46. Castellano JM, Sanz G, Peñalvo JL, et al. A polypill strategy to improve 
adherence: results from the FOCUS project. J Am Coll Cardiol. 2014; 
64(20):2071–2082.
 47. Gwadry-Sridhar FH, Manias E, Lal L, et al. Impact of interventions 
on medication adherence and blood pressure control in patients with 
essential hypertension: a systematic review by the ISPOR medication 
adherence and persistence special interest group. Value Health. 2013; 
16(5):863–871.
 48. Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness 
of fixed-dose combinations of antihypertensive agents: a meta-analysis. 
Hypertension. 2010;55(2):399–407.
 49. Krousel-Wood M, Joyce C, Holt E, et al. Predictors of decline in medica-
tion adherence: results from the cohort study of medication adherence 
among older adults. Hypertension. 2011;58(5):804–810.
 50. Bauer LK, Caro MA, Beach SR, et al. Effects of depression and anxiety 
improvement on adherence to medication and health behaviors in 

































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1
